Tet2 disruption improves Kymriah efficacy

In a Nature study, researchers at the University of Pennsylvania identified a patient with an enhanced response to CAR T therapy Kymriah tisagenlecleucel, and suggested targeting the epigenome by inhibiting Tet2 could improve the efficacy of CAR T therapies.

The paper's authors include CAR T pioneer Carl June, whose research led to the development of Kymriah, which Novartis AG (NYSE:NVS; SIX:NOVN) licensed from UPenn...